Cargando…

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma

BRAF inhibitor (BRAFi) has been used for treatment of melanomas harboring V600E mutation. Despite a high initial response rate, resistance to BRAFi is inevitable. Here, we demonstrate that BRAFi-resistant (BR) melanomas are susceptible to arginine deprivation due to inability to initiate re-expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ying-Ying, Wu, Chunjing, Chen, Shu-Mei, Shah, Sumedh S., Wangpaichitr, Medhi, Feun, Lynn G., Kuo, Macus T., Suarez, Miguel, Prince, Jeffrey, Savaraj, Niramol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951241/ https://www.ncbi.nlm.nih.gov/pubmed/26771234 http://dx.doi.org/10.18632/oncotarget.6882

Ejemplares similares

Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
por: Li, Ying‐Ying, et al.
Publicado: (2017)

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
por: Wu, Chunjing, et al.
Publicado: (2021)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer
por: Wangpaichitr, Medhi, et al.
Publicado: (2017)

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
por: Kuo, Macus Tien, et al.
Publicado: (2010)

Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy
por: Li, Ying-Ying, et al.
Publicado: (2017)

Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
por: Wangpaichitr, Medhi, et al.
Publicado: (2021)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy
por: Kuo, Macus Tien, et al.
Publicado: (2021)

N′(1),N′(3)-Dimethyl-N′(1),N′(3)-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)
por: Wangpaichitr, Medhi, et al.
Publicado: (2009)

Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
por: Kuo, Macus Tien, et al.
Publicado: (2019)

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation
por: Long, Yan, et al.
Publicado: (2016)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor
por: Wangpaichitr, Medhi, et al.
Publicado: (2002)

Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression
por: Tsai, Wen-Bin, et al.
Publicado: (2017)

Arginine deprivation therapy for malignant melanoma
por: Yoon, Jung-Ki, et al.
Publicado: (2012)

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
por: Wu, Chunjing, et al.
Publicado: (2023)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know
por: Bhatia, Shivank, et al.
Publicado: (2016)

Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals
por: Liang, Zheng Dong, et al.
Publicado: (2013)

Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer
por: Wangpaichitr, M, et al.
Publicado: (2017)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Gas6/Axl in arginine-starvation therapy
por: Tsai, Wen-Bin, et al.
Publicado: (2015)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Lee, Le Min, et al.
Publicado: (2014)

Optimizing arginine deprivation for hard-to-treat cancers
por: Khadeir, Ramsay, et al.
Publicado: (2017)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Bench-to-Bedside Studies of Arginine Deprivation in Cancer
por: Field, George C., et al.
Publicado: (2023)

Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors
por: Hajji, Nabil, et al.
Publicado: (2022)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Deprivation of arginine by recombinant human arginase in prostate cancer cells
por: Hsueh, Eddy C, et al.
Publicado: (2012)

Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
por: Sun, Naihui, et al.
Publicado: (2022)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ds929kkc7u2arq0gfgmuuat84r